UY27772A1 - Inhibidores triariloxiariloxipirimidin-2,4,6- triona de metaloproteinasa. - Google Patents

Inhibidores triariloxiariloxipirimidin-2,4,6- triona de metaloproteinasa.

Info

Publication number
UY27772A1
UY27772A1 UY27772A UY27772A UY27772A1 UY 27772 A1 UY27772 A1 UY 27772A1 UY 27772 A UY27772 A UY 27772A UY 27772 A UY27772 A UY 27772A UY 27772 A1 UY27772 A1 UY 27772A1
Authority
UY
Uruguay
Prior art keywords
inhibitors
triariloxiariloxipirimidin
triona
metaloproteinase
triaryloxyaryloxypyrimidin
Prior art date
Application number
UY27772A
Other languages
English (en)
Inventor
Lawrence A Reiter
Kevin D Freeman-Cook
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY27772A1 publication Critical patent/UY27772A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a inhibidores triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa de fórmula en la que X,A,Y,B,G,W,y R1 son como se definen en la memoria descriptiva, y a composiciones farmacéuticas y procedimientos de tratamiento de la inflamación, en cáncer y otros trastornos.
UY27772A 2002-04-26 2003-04-23 Inhibidores triariloxiariloxipirimidin-2,4,6- triona de metaloproteinasa. UY27772A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37599002P 2002-04-26 2002-04-26

Publications (1)

Publication Number Publication Date
UY27772A1 true UY27772A1 (es) 2003-11-28

Family

ID=29270744

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27772A UY27772A1 (es) 2002-04-26 2003-04-23 Inhibidores triariloxiariloxipirimidin-2,4,6- triona de metaloproteinasa.

Country Status (18)

Country Link
US (1) US7119201B2 (es)
EP (1) EP1501515B1 (es)
JP (1) JP2005529132A (es)
AR (1) AR039658A1 (es)
AT (1) ATE308325T1 (es)
AU (1) AU2003216677A1 (es)
BR (1) BR0309386A (es)
CA (1) CA2484067A1 (es)
DE (1) DE60302149T2 (es)
DO (1) DOP2003000621A (es)
ES (1) ES2250880T3 (es)
GT (1) GT200300082A (es)
MX (1) MXPA04009392A (es)
NI (1) NI200300045A (es)
PA (1) PA8571501A1 (es)
TW (1) TW200403998A (es)
UY (1) UY27772A1 (es)
WO (1) WO2003090752A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2483075A1 (en) 2002-04-26 2003-11-06 Pfizer Products Inc. Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
CA2480092A1 (en) * 2002-04-26 2003-11-06 Pfizer Products Inc. N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
CA2483500A1 (en) * 2002-04-26 2003-11-06 Pfizer Products Inc. Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
DE602005025755D1 (de) * 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
JP5063351B2 (ja) * 2004-09-17 2012-10-31 エグゼリクシス， インコーポレイテッド ピラゾールキナーゼモジュレーターおよび使用方法
US9045442B2 (en) 2007-12-21 2015-06-02 University Of Notre Dame Du Lac Antibacterial compounds and methods of using same
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
GB201115937D0 (en) 2011-09-14 2011-10-26 Univ Aberdeen 18F-labelled compounds for use as positron emission imaging agents
WO2015123003A1 (en) 2014-02-14 2015-08-20 Warrell Raymond P Bifunctional compounds and use for reducing uric acid levels
US10600505B2 (en) 2014-02-21 2020-03-24 Medicomp Systems, Inc. Intelligent prompting of protocols
JP2017533187A (ja) 2014-09-25 2017-11-09 ユニヴァーシティー オブ ノートル ダム デュ ラック 非β−ラクタム系抗生物質
EP3247704A4 (en) 2015-01-22 2018-10-03 Acquist LLC Bifunctional compounds and use for reducing uric acid levels
TWI771303B (zh) 2016-06-30 2022-07-21 美商艾克奎斯特有限責任公司 化合物及其於降低尿酸位準之用途(一)
TWI749024B (zh) 2016-07-06 2021-12-11 美商艾克奎斯特有限責任公司 化合物及其於降低尿酸位準之用途
US11168062B2 (en) 2016-09-12 2021-11-09 University Of Notre Dame Du Lac Compounds for the treatment of Clostridium difficile infection
SI3700902T1 (sl) 2017-10-27 2023-10-30 Boehringer Ingelheim International Gmbh Inhibitorji trpc6

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
DE19548624A1 (de) * 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE69831233T2 (de) * 1997-06-21 2006-06-01 Roche Diagnostics Gmbh Barbitursaure derivaten mit antimetastatischer und antitumorischer wirkung
US6265578B1 (en) * 1999-02-12 2001-07-24 Hoffmann-La Roche Inc. Pyrimidine-2,4,6-triones
PA8498701A1 (es) 1999-08-12 2002-08-26 Pfizer Prod Inc Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
US6841671B2 (en) 2000-10-26 2005-01-11 Pfizer Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
BR0114917A (pt) 2000-10-26 2003-07-01 Pfizer Prod Inc Inibidores de pirimidina-2,4,6-triona metaloproteinase
CA2480092A1 (en) 2002-04-26 2003-11-06 Pfizer Products Inc. N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
CA2483075A1 (en) 2002-04-26 2003-11-06 Pfizer Products Inc. Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors

Also Published As

Publication number Publication date
TW200403998A (en) 2004-03-16
ATE308325T1 (de) 2005-11-15
BR0309386A (pt) 2005-02-22
CA2484067A1 (en) 2003-11-06
DE60302149D1 (de) 2005-12-08
PA8571501A1 (es) 2003-12-10
MXPA04009392A (es) 2005-01-25
JP2005529132A (ja) 2005-09-29
ES2250880T3 (es) 2006-04-16
AR039658A1 (es) 2005-03-02
US7119201B2 (en) 2006-10-10
AU2003216677A1 (en) 2003-11-10
US20040006057A1 (en) 2004-01-08
WO2003090752A1 (en) 2003-11-06
DE60302149T2 (de) 2006-07-20
DOP2003000621A (es) 2003-10-31
EP1501515A1 (en) 2005-02-02
GT200300082A (es) 2004-04-19
EP1501515B1 (en) 2005-11-02
NI200300045A (es) 2005-07-08

Similar Documents

Publication Publication Date Title
UY27775A1 (es) Inhibidores de metaloproteinasa de aril-heteroariloxi-ariloxi-pirimidina-2,4,6-triona
UY26285A1 (es) Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
ECSP034568A (es) Inhibidores de metaloproteinasa del tipo pirimidin 2,4,6-triona
BR0308787A (pt) Inibidores de metaloproteinase de n-substituìdos-heteroarilóxi-aril-espiro-pirimidina- 2,4,6-triona
UY27772A1 (es) Inhibidores triariloxiariloxipirimidin-2,4,6- triona de metaloproteinasa.
UY27774A1 (es) Inhibidores de metaloproteinas de triaril-oxi-aril-espiropirimidina-2,4,6-triona
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
YU37904A (sh) Benzimidazoli kao korisni inhibitori proteinske kinaze
MX2007014920A (es) Politerapia que comprende diarilureas para el tratamiento de enfermedades.
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
ATE443044T1 (de) Tace inhibitoren
BR0309996A (pt) Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias
DE60226313D1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
BRPI0507985A (pt) derivados de piperazina uréia para o tratamento de endometriose
ATE348803T1 (de) Tryptase-inhibitoren
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
BRPI0414423A (pt) inibidores de pace4, suas composições farmacêuticas e respectivos usos
DOP2003000634A (es) Inhibidores de metaloproteinasa de triaril-oxiaril-espiro-pirimidina-2,4,6-triona
DOP2003000633A (es) Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-trionan-sustituida
CR6940A (es) Inhibidores de espiropirimidin-2,4,6-triona metaloproteinasa
ATE327240T1 (de) 2ß OXO-VORUSCHARIN UND DERIVATEN
ECSP003382A (es) Compuestos utiles como antiinflamatorios
CY1114825T1 (el) Συνθεσεις και μεθοδοι αγωγης διαταραχων υπερπλασιας κυτταρων
TW200510348A (en) 5-aryltetrazole compounds, compositions thereof, and uses therefor

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150224